© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
A recent study analyzed kidney parameters among those with HIV who were treated for hep C with the regimen.
The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).
Starting treatment within four months of infection also predicted a better resurgence of CD4 cells.
The U.S. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents has come nearly full circle...
In honor of World AIDS Day, AIDSmeds highlights the year’s top treatment stories.
People who switched from a protease inhibitor (PI) to Isentress (raltegravir) did well regardless of whether they switched to a once-daily o...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
